FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2765744530> ?p ?o ?g. }

• W2765744530 endingPage "e0185753" @default.
• W2765744530 startingPage "e0185753" @default.
• W2765744530 abstract "The Prosigna® breast cancer prognostic gene signature assay identifies a gene-expression profile that permits the classification of tumors into subtypes and gives a score for the risk of recurrence (ROR) at 10 years. The primary objective of this multicenter study was to evaluate the impact of Prosigna's assay information on physicians' adjuvant treatment decisions in patients with early-stage breast cancer. Secondary objectives were to assess confidence of practitioners in their therapeutic recommendations before and after the added information provided by the Prosigna assay; and to evaluate the emotional state of patients before and after the Prosigna test results.Consecutive patients with invasive early-stage breast cancer were enrolled in a prospective, observational, multicenter study carried out in 8 hospitals in France. The Prosigna test was carried out on surgical specimens using the nCounter® Analysis System located at the Institut Curie. Both before and after receiving the Prosigna test results, physicians completed treatment confidence questionnaires and patients completed questionnaires concerning their state of anxiety, the difficulties felt in face of the therapy and quality of life. Information was also collected at 6 months regarding the physicians' opinion on the test results and the patients' degree of anxiety, difficulties with therapy and quality of life.Between March 2015 and January 2016, 8 study centers in France consecutively enrolled 210 postmenopausal women with estrogen receptor (ER) positive, human epidermal growth hormone-2 (HER-2) negative, and node negative tumors, either stage 1 or stage 2. Intrinsic tumor subtypes as assessed by the Prosigna test were 114 (58.2%) Luminal A, 79 (40.3%) Luminal B, 1 (0.5%) HER-2 enriched (HER-2E), and 2 (1.0%) basal-like. Before receiving the Prosigna test results, physicians categorized tumor subtypes based on immunohistochemistry (IHC) as Luminal A in 126 (64%) patients and Luminal B in 70 (36%) patients, an overall discordance rate of 25%. The availability of Prosigna assay results was significantly associated with the likelihood of change in treatment recommendations, with 34 patients (18%) having their treatment plan changed from Adjuvant Chemotherapy to No Adjuvant Chemotherapy or vice versa (p<0.001, Fisher's exact test). Prosigna test results also decreased patients' anxiety about the chosen adjuvant therapy, and improved emotional well-being and measures of personal perceptions of uncertainty.The results of this prospective decision impact study are consistent with 2 previous, identically designed studies carried out in Spain and Germany. The availability of Prosigna test results increased the confidence of treating physicians in their adjuvant treatment decisions, and led to an 18% change in chemotherapy treatment plan (from Adjuvant Chemotherapy to No Adjuvant Chemotherapy or vice versa). Prosigna testing decreased anxiety and improved measures of health-related quality of life in patients facing adjuvant therapy. The 25% discordance between Prosigna test and IHC subtyping underlines the importance of molecular testing for optimal systemic therapy indications in early breast cancer." @default.
• W2765744530 created "2017-11-10" @default.
• W2765744530 creator A5015020497 @default.
• W2765744530 creator A5015160128 @default.
• W2765744530 creator A5018057485 @default.
• W2765744530 creator A5018155601 @default.
• W2765744530 creator A5025546051 @default.
• W2765744530 creator A5027696743 @default.
• W2765744530 creator A5030807365 @default.
• W2765744530 creator A5030928151 @default.
• W2765744530 creator A5031564329 @default.
• W2765744530 creator A5034058277 @default.
• W2765744530 creator A5041406286 @default.
• W2765744530 creator A5041932927 @default.
• W2765744530 creator A5049413823 @default.
• W2765744530 creator A5050906584 @default.
• W2765744530 creator A5052876034 @default.
• W2765744530 creator A5060909413 @default.
• W2765744530 creator A5061340891 @default.
• W2765744530 creator A5069540694 @default.
• W2765744530 creator A5071567585 @default.
• W2765744530 creator A5075347831 @default.
• W2765744530 creator A5080332706 @default.
• W2765744530 creator A5081602128 @default.
• W2765744530 creator A5082275352 @default.
• W2765744530 date "2017-10-18" @default.
• W2765744530 modified "2023-10-09" @default.
• W2765744530 title "Prospective, multicenter French study evaluating the clinical impact of the Breast Cancer Intrinsic Subtype-Prosigna® Test in the management of early-stage breast cancers" @default.
• W2765744530 cites W1444168786 @default.
• W2765744530 cites W2027554591 @default.
• W2765744530 cites W2044702943 @default.
• W2765744530 cites W2092624579 @default.
• W2765744530 cites W2097255042 @default.
• W2765744530 cites W2105258029 @default.
• W2765744530 cites W2117775530 @default.
• W2765744530 cites W2118632896 @default.
• W2765744530 cites W2118812883 @default.
• W2765744530 cites W2128458647 @default.
• W2765744530 cites W2131994307 @default.
• W2765744530 cites W2140628034 @default.
• W2765744530 cites W2157840751 @default.
• W2765744530 cites W2159846010 @default.
• W2765744530 cites W2161518426 @default.
• W2765744530 cites W2171638840 @default.
• W2765744530 cites W2173858545 @default.
• W2765744530 cites W2185002853 @default.
• W2765744530 cites W2236134270 @default.
• W2765744530 cites W2259802687 @default.
• W2765744530 cites W2267844613 @default.
• W2765744530 cites W2319824849 @default.
• W2765744530 cites W2497616908 @default.
• W2765744530 cites W2509844702 @default.
• W2765744530 cites W2594329947 @default.
• W2765744530 cites W4233274666 @default.
• W2765744530 cites W4252714226 @default.
• W2765744530 cites W4376596040 @default.
• W2765744530 doi "https://doi.org/10.1371/journal.pone.0185753" @default.
• W2765744530 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5646764" @default.
• W2765744530 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29045452" @default.
• W2765744530 hasPublicationYear "2017" @default.
• W2765744530 type Work @default.
• W2765744530 sameAs 2765744530 @default.
• W2765744530 citedByCount "15" @default.
• W2765744530 countsByYear W27657445302017 @default.
• W2765744530 countsByYear W27657445302019 @default.
• W2765744530 countsByYear W27657445302020 @default.
• W2765744530 countsByYear W27657445302021 @default.
• W2765744530 countsByYear W27657445302022 @default.
• W2765744530 countsByYear W27657445302023 @default.
• W2765744530 crossrefType "journal-article" @default.
• W2765744530 hasAuthorship W2765744530A5015020497 @default.
• W2765744530 hasAuthorship W2765744530A5015160128 @default.
• W2765744530 hasAuthorship W2765744530A5018057485 @default.
• W2765744530 hasAuthorship W2765744530A5018155601 @default.
• W2765744530 hasAuthorship W2765744530A5025546051 @default.
• W2765744530 hasAuthorship W2765744530A5027696743 @default.
• W2765744530 hasAuthorship W2765744530A5030807365 @default.
• W2765744530 hasAuthorship W2765744530A5030928151 @default.
• W2765744530 hasAuthorship W2765744530A5031564329 @default.
• W2765744530 hasAuthorship W2765744530A5034058277 @default.
• W2765744530 hasAuthorship W2765744530A5041406286 @default.
• W2765744530 hasAuthorship W2765744530A5041932927 @default.
• W2765744530 hasAuthorship W2765744530A5049413823 @default.
• W2765744530 hasAuthorship W2765744530A5050906584 @default.
• W2765744530 hasAuthorship W2765744530A5052876034 @default.
• W2765744530 hasAuthorship W2765744530A5060909413 @default.
• W2765744530 hasAuthorship W2765744530A5061340891 @default.
• W2765744530 hasAuthorship W2765744530A5069540694 @default.
• W2765744530 hasAuthorship W2765744530A5071567585 @default.
• W2765744530 hasAuthorship W2765744530A5075347831 @default.
• W2765744530 hasAuthorship W2765744530A5080332706 @default.
• W2765744530 hasAuthorship W2765744530A5081602128 @default.
• W2765744530 hasAuthorship W2765744530A5082275352 @default.
• W2765744530 hasBestOaLocation W27657445301 @default.
• W2765744530 hasConcept C118552586 @default.
• W2765744530 hasConcept C121608353 @default.
• W2765744530 hasConcept C126322002 @default.
• W2765744530 hasConcept C143998085 @default.

• next